• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

SULFASALAZINE Drug Record

  • Summary
  • Interactions
  • Claims
  • SULFASALAZINE chembl:CHEMBL421 ApprovedImmunotherapy

    Alternate Names:

    SULFASALAZINE
    NSC-667219
    SALAZOPYRIN-EN
    SALAZOSULFAPYRIDINE
    AZULFIDINE EN
    AZULFIDINE EN-TABS
    SAS-500
    COLIZINE
    SALAZOPYRIN
    S.A.S.
    SULPHASALAZINE
    UCINE
    AZULFIDINE
    S.A.S.-500
    SALAZOPYRIN E.C.
    NSC-203730
    SALICYLAZOSULFAPYRIDINE
    SALAZOSULFAPYRIDINUM
    SULFASALAZINA
    SALAZOPYRIN®
    2-HYDROXY-5-[4-(PYRIDIN-2-YLSULFAMOYL)-PHENYLAZO]-BENZOIC ACID
    AZULFIDINE®
    5-(P-(2-PYRIDYLSULFAMYL)PHENYLAZO)SALICYLIC ACID
    SULFASALAZINUM
    AZOPYRIN
    SULFASALAZIN
    4-(PYRIDYL-2-AMIDOSULFONYL)-3'-CARBOXY-4'-HYDROXYAZOBENZENE
    5-(4-(2-PYRIDYLSULFAMOYL)PHENYLAZO)-2-HYDROXYBENZOIC ACID
    2-HYDROXY-5-((4-((2-PYRIDINYLAMINO)SULFONYL)PHENYL)AZO)BENZOIC ACID
    SALAZOSULFAPIRIDINA
    5-((P-(2-PYRIDYLSULFAMOYL)PHENYL)AZO)SALICYLIC ACID
    SALAZOPYRIDIN®
    rxcui:9524
    pubchem.compound:5353980
    chemidplus:599-79-1
    chembl:CHEMBL421
    drugbank:00795

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antiinflammatory agent,DMARD
    Drug Class antirheumatic agents
    Year of Approval 1950
    Drug Class anti-inflammatory agents, non-steroidal
    (5 More Sources)

    Publications:

    Schwahn B et al., 2001, Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences., Am J Pharmacogenomics
    Matasić et al., 2001, Maturation of human dendritic cells as sulfasalazine target., Croat. Med. J.
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Faison et al., 1992, Sulfasalazine inhibits lyso-PAF: acetyl-COA acetyltransferase., Prostaglandins
    Allgayer et al., 1984, Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine., Eur. J. Clin. Pharmacol.
    Nielsen et al., 1987, Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid., Dig. Dis. Sci.
    Sircar et al., 1983, Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis., Biochem. Pharmacol.
    Allgayer, 2003, Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease., Aliment. Pharmacol. Ther.
    Distrutti et al., 2006, 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity., J. Pharmacol. Exp. Ther.
    Mifflin et al., 2004, Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts., Mol. Pharmacol.
    Generini et al., Therapy of spondylarthropathy in inflammatory bowel disease., Clin. Exp. Rheumatol.
    Pruzanski et al., 1997, Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity., Biochem. Pharmacol.
    Cipolla et al., 2002, Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives., Pharmacol. Res.
    Kashihara Y et al., 2017, Small-Dosing Clinical Study: Pharmacokinetic, Pharmacogenomic (SLCO2B1 and ABCG2), and Interaction (Atorvastatin and Grapefruit Juice) Profiles of 5 Probes for OATP2B1 and BCRP., J Pharm Sci
    Gotanda K et al., 2015, Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in the ABCG2 gene., Br J Clin Pharmacol
    Wiese MD et al., 2014, Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis., Pharmacogenomics J
    Yamasaki Y et al., 2008, Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans., Clin Pharmacol Ther
    Selhub et al., 1978, Inhibition of folate enzymes by sulfasalazine., J. Clin. Invest.
    Cohen SM et al., 1968, Ulcerative colitis and erythrocyte G6PD deficiency. Salicylazosulfapyridine-provoked hemolysis., JAMA
    Morabito et al., 1998, Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides., J. Clin. Invest.
    de Bruin et al., 2004, Sulfasalazine down-regulates the expression of the angiogenic factors platelet-derived endothelial cell growth factor/thymidine phosphorylase and interleukin-8 in human monocytic-macrophage THP1 and U937 cells., Mol. Pharmacol.
    James HM et al., 2008, Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis., J Rheumatol
    Yang F et al., 2014, HLA-B*13:01 is associated with salazosulfapyridine-induced drug rash with eosinophilia and systemic symptoms in Chinese Han population., Pharmacogenomics
    Rousseaux et al., 2005, Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma., J. Exp. Med.
    Linard et al., 2008, Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist., J. Pharmacol. Exp. Ther.
    Desreumaux et al., 2006, Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence., Aliment. Pharmacol. Ther.
    Schwab et al., 2008, PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells., Carcinogenesis
  • SULFASALAZINE   ACAT1

    Interaction Score: 13.44

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name sulfasalazine,Azulfidine, Salazopyrin
    Novel drug target Established target

    PMIDs:
    17016423 17139284 1357724


    Sources:
    TdgClinicalTrial TEND

  • SULFASALAZINE   CD83

    Interaction Score: 5.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11471196


    Sources:
    NCI

  • SULFASALAZINE   TYMP

    Interaction Score: 0.9

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15269287


    Sources:
    NCI

  • SULFASALAZINE   ALOX5

    Interaction Score: 0.43

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Arachidonate 5-lipoxygenase inhibitor

    PMIDs:
    6428914 2882965 6131674


    Sources:
    ChemblInteractions

  • SULFASALAZINE   TYMSOS

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18322994


    Sources:
    PharmGKB

  • SULFASALAZINE   NT5E

    Interaction Score: 0.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9435300


    Sources:
    NCI

  • SULFASALAZINE   DHFR

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22555


    Sources:
    NCI

  • SULFASALAZINE   ABCG2

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28322941 25872459 24394199 18167504


    Sources:
    PharmGKB TTD

  • SULFASALAZINE   PTGS2

    Interaction Score: 0.23

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name sulfasalazine,Azulfidine, Salazopyrin
    Novel drug target Established target
    Mechanism of Interaction Cyclooxygenase inhibitor

    PMIDs:
    16855178 14742690 12463455 9256165 12208114


    Sources:
    TdgClinicalTrial ChemblInteractions

  • SULFASALAZINE   HLA-B

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25303297


    Sources:
    PharmGKB

  • SULFASALAZINE   MTHFR

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12083967


    Sources:
    PharmGKB

  • SULFASALAZINE   TYMS

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18322994


    Sources:
    PharmGKB

  • SULFASALAZINE   PTGS1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Cyclooxygenase inhibitor
    Novel drug target Established target

    PMIDs:
    12950415


    Sources:
    TdgClinicalTrial ChemblInteractions

  • SULFASALAZINE   G6PD

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    4386139


    Sources:
    PharmGKB FDA

  • SULFASALAZINE   PPARG

    Interaction Score: 0.11

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name sulfasalazine,Azulfidine, Salazopyrin
    Novel drug target Established target

    PMIDs:
    15824083 18077625 16939423 18544567


    Sources:
    TdgClinicalTrial

  • SULFASALAZINE   NFKB2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • SULFASALAZINE   HIF1A

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SULFASALAZINE   CYP2C9

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • SULFASALAZINE   HPGD

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SULFASALAZINE   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • SULFASALAZINE   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • SULFASALAZINE   MAPT

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • SULFASALAZINE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • TEND: SULFASALAZINE

    • Version: 01-August-2011

    Alternate Names:
    SULFASALAZINE Primary Drug Name

    Drug Info:
    Drug Class anti-inflammatory agents, non-steroidal
    Year of Approval 1950
    Drug Class antirheumatic agents

    Publications:

  • TdgClinicalTrial: SULFASALAZINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antiinflammatory agent,DMARD
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: SULFASALAZINE

    • Version: 14-September-2017

    Alternate Names:
    C29469 NCI drug code

    Drug Info:

    Publications:
    Matasić et al., 2001, Maturation of human dendritic cells as sulfasalazine target., Croat. Med. J.
    de Bruin et al., 2004, Sulfasalazine down-regulates the expression of the angiogenic factors platelet-derived endothelial cell growth factor/thymidine phosphorylase and interleukin-8 in human monocytic-macrophage THP1 and U937 cells., Mol. Pharmacol.
    Selhub et al., 1978, Inhibition of folate enzymes by sulfasalazine., J. Clin. Invest.

  • DTC: SULFASALAZINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL421 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • PharmGKB: sulfasalazine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Schwahn B et al., 2001, Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences., Am J Pharmacogenomics
    Cohen SM et al., 1968, Ulcerative colitis and erythrocyte G6PD deficiency. Salicylazosulfapyridine-provoked hemolysis., JAMA
    Gotanda K et al., 2015, Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in the ABCG2 gene., Br J Clin Pharmacol

  • TTD: Sulfasalazine

    • Version: 2020.06.01

    Alternate Names:
    D02ZTJ TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL421

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Sulfasalazine

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL421

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21